PubRank

Frank M Torti

Author PubWeight™ 88.62‹?›

Top papers

Rank Title Journal Year PubWeight™‹?›
1 Antiandrogen withdrawal alone or in combination with ketoconazole in androgen-independent prostate cancer patients: a phase III trial (CALGB 9583). J Clin Oncol 2004 4.25
2 Ferritin heavy chain upregulation by NF-kappaB inhibits TNFalpha-induced apoptosis by suppressing reactive oxygen species. Cell 2004 3.21
3 Iron and cancer: more ore to be mined. Nat Rev Cancer 2013 2.40
4 Potential impact of adding genetic markers to clinical parameters in predicting prostate biopsy outcomes in men following an initial negative biopsy: findings from the REDUCE trial. Eur Urol 2012 2.34
5 Binding and uptake of H-ferritin are mediated by human transferrin receptor-1. Proc Natl Acad Sci U S A 2010 1.99
6 Curcumin, a cancer chemopreventive and chemotherapeutic agent, is a biologically active iron chelator. Blood 2008 1.97
7 Ferroportin and iron regulation in breast cancer progression and prognosis. Sci Transl Med 2010 1.94
8 An iron regulatory gene signature predicts outcome in breast cancer. Cancer Res 2011 1.91
9 Low to moderate dose anthracycline-based chemotherapy is associated with early noninvasive imaging evidence of subclinical cardiovascular disease. JACC Cardiovasc Imaging 2013 1.82
10 Serum ferritin: Past, present and future. Biochim Biophys Acta 2010 1.80
11 Iron chelators in cancer chemotherapy. Curr Top Med Chem 2004 1.61
12 TIM-2 is expressed on B cells and in liver and kidney and is a receptor for H-ferritin endocytosis. J Exp Med 2005 1.52
13 Prostate cancer risk associated loci in African Americans. Cancer Epidemiol Biomarkers Prev 2009 1.49
14 Ferritin for the clinician. Blood Rev 2008 1.46
15 Demand for continuing medical education programs on cancer care among primary care physicians in North Carolina. N C Med J 2004 1.46
16 Long-term survival following a single treatment of kidney tumors with multiwalled carbon nanotubes and near-infrared radiation. Proc Natl Acad Sci U S A 2009 1.41
17 Regulatory effects of ferritin on angiogenesis. Proc Natl Acad Sci U S A 2009 1.34
18 Phase II trial of radio frequency ablation of renal cancer: evaluation of the kill zone. J Urol 2002 1.30
19 Ironing out cancer. Cancer Res 2011 1.25
20 Nrf2 mediates the induction of ferritin H in response to xenobiotics and cancer chemopreventive dithiolethiones. J Biol Chem 2002 1.23
21 A systems biology view of cancer. Biochim Biophys Acta 2009 1.17
22 Iron chelation in the biological activity of curcumin. Free Radic Biol Med 2006 1.17
23 The role of iron chelation in cancer therapy. Curr Med Chem 2003 1.15
24 Excess capacity of the iron regulatory protein system. J Biol Chem 2007 1.14
25 Aortic stiffness increases upon receipt of anthracycline chemotherapy. J Clin Oncol 2009 1.14
26 Mouse brains deficient in H-ferritin have normal iron concentration but a protein profile of iron deficiency and increased evidence of oxidative stress. J Neurosci Res 2003 1.13
27 Conducting economic evaluations alongside multinational clinical trials: toward a research consensus. Am Heart J 2005 1.12
28 The transplant iron score as a predictor of stem cell transplant survival. J Hematol Oncol 2009 1.10
29 Bioinformatics tools for cancer metabolomics. Metabolomics 2011 1.10
30 Thermal ablation therapeutics based on CN(x) multi-walled nanotubes. Int J Nanomedicine 2007 1.09
31 Tachpyridine, a metal chelator, induces G2 cell-cycle arrest, activates checkpoint kinases, and sensitizes cells to ionizing radiation. Blood 2005 1.08
32 Novel approach to early detection of doxorubicin cardiotoxicity by gadolinium-enhanced cardiovascular magnetic resonance imaging in an experimental model. Circ Cardiovasc Imaging 2010 1.05
33 Phase I and pharmacokinetic study of angiotensin-(1-7), an endogenous antiangiogenic hormone. Clin Cancer Res 2009 1.04
34 A general map of iron metabolism and tissue-specific subnetworks. Mol Biosyst 2009 1.02
35 A human bone morphogenetic protein antagonist is down-regulated in renal cancer. Mol Biol Cell 2007 1.01
36 Phase I/II study of 19-nor-1alpha-25-dihydroxyvitamin D2 (paricalcitol) in advanced, androgen-insensitive prostate cancer. Clin Cancer Res 2005 1.01
37 Cleavage of high-molecular-weight kininogen by elastase and tryptase is inhibited by ferritin. Am J Physiol Lung Cell Mol Physiol 2008 1.01
38 The resistance of breast cancer stem cells to conventional hyperthermia and their sensitivity to nanoparticle-mediated photothermal therapy. Biomaterials 2012 0.97
39 Phase I-II prospective dose-escalating trial of lycopene in patients with biochemical relapse of prostate cancer after definitive local therapy. Urology 2006 0.97
40 Synthetic and natural iron chelators: therapeutic potential and clinical use. Future Med Chem 2009 0.94
41 IRP2 regulates breast tumor growth. Cancer Res 2013 0.94
42 Activation of caspase pathways during iron chelator-mediated apoptosis. J Biol Chem 2002 0.94
43 Development of iron-containing multiwalled carbon nanotubes for MR-guided laser-induced thermotherapy. Nanomedicine (Lond) 2011 0.92
44 Determinants of the thrombogenic potential of multiwalled carbon nanotubes. Biomaterials 2011 0.92
45 Serum levels of phytanic acid are associated with prostate cancer risk. Prostate 2005 0.92
46 Post-transcriptional modulation of iron homeostasis during p53-dependent growth arrest. J Biol Chem 2008 0.90
47 Ferritin binds to light chain of human H-kininogen and inhibits kallikrein-mediated bradykinin release. Biochem J 2002 0.89
48 Angiotensin-(1-7) attenuates metastatic prostate cancer and reduces osteoclastogenesis. Prostate 2012 0.89
49 Iron uptake mediated by binding of H-ferritin to the TIM-2 receptor in mouse cells. PLoS One 2011 0.89
50 SOSTDC1 differentially modulates Smad and beta-catenin activation and is down-regulated in breast cancer. Breast Cancer Res Treat 2010 0.89
51 Tissue-specific expression of ferritin H regulates cellular iron homoeostasis in vivo. Biochem J 2006 0.89
52 Health system correlates of receipt of radiation therapy after breast-conserving surgery: a study of low-income Medicaid-enrolled women. Am J Manag Care 2008 0.88
53 Role of zinc and iron chelation in apoptosis mediated by tachpyridine, an anti-cancer iron chelator. Biochem Pharmacol 2004 0.88
54 A novel cytostatic form of autophagy in sensitization of non-small cell lung cancer cells to radiation by vitamin D and the vitamin D analog, EB 1089. Autophagy 2014 0.88
55 A Phase I/II study of GTI-2040 and capecitabine in patients with renal cell carcinoma. Cancer Chemother Pharmacol 2007 0.87
56 Angiotensin-(1-7) reduces proliferation and angiogenesis of human prostate cancer xenografts with a decrease in angiogenic factors and an increase in sFlt-1. Prostate 2012 0.86
57 Prostate cancer and bone metastases: medical treatment. Clin Orthop Relat Res 2003 0.85
58 Ferritin blocks inhibitory effects of two-chain high molecular weight kininogen (HKa) on adhesion and survival signaling in endothelial cells. PLoS One 2012 0.84
59 Ferritin regulation by oxidants and chemopreventive xenobiotics. Adv Enzyme Regul 2003 0.83
60 Loss of heterozygosity and SOSTDC1 in adult and pediatric renal tumors. J Exp Clin Cancer Res 2010 0.82
61 Ferritin H induction by histone deacetylase inhibitors. Biochem Pharmacol 2010 0.82
62 Ferritin H is a novel marker of early erythroid precursors and macrophages. Histopathology 2013 0.81
63 Oxathiolene oxides: a novel family of compounds that induce ferritin, glutathione S-transferase, and other proteins of the phase II response. Biochem Pharmacol 2003 0.81
64 Bone metastases in prostate cancer: a targeted approach. Curr Opin Oncol 2007 0.81
65 Cellular iron metabolism in prognosis and therapy of breast cancer. Crit Rev Oncog 2013 0.80
66 Preliminary evaluation of the cytotoxicity of a series of tris-2-aminoethylamine (Tren) based hexadentate heterocyclic donor agents. Bioorg Med Chem 2005 0.80
67 Vinorelbine, doxorubicin, and prednisone in androgen-independent prostate cancer. Cancer 2006 0.79
68 Synthesis and potent antitumor activities of novel 1,3,5-cis,cis-triaminocyclohexane N-pyridyl derivatives. J Med Chem 2004 0.79
69 Weekly doxorubicin increases coronary arteriolar wall and adventitial thickness. PLoS One 2013 0.79
70 Synthesis of 1,3,5-cis,cis-triaminocyclohexane N-pyridyl derivatives as potential antitumor agents. J Org Chem 2002 0.78
71 Radiofrequency ablation of isolated local recurrence of renal cell carcinoma after radical nephrectomy. AJR Am J Roentgenol 2003 0.77
72 Phase II trial of combination interferon-alpha and thalidomide as first-line therapy in metastatic renal cell carcinoma. Urology 2004 0.77
73 Application of circuit simulation method for differential modeling of TIM-2 iron uptake and metabolism in mouse kidney cells. Front Physiol 2013 0.76
74 Coordinate inhibition of cytokine-mediated induction of ferritin H, manganese superoxide dismutase, and interleukin-6 by the adenovirus E1A oncogene. J Biol Chem 2006 0.76
75 Influence of ligand structure on Fe(II) spin-state and redox rate in cytotoxic tripodal chelators. J Inorg Biochem 2007 0.75
76 The high-molecular-weight kininogen domain 5 is an intrinsically unstructured protein and its interaction with ferritin is metal mediated. Protein Sci 2014 0.75
77 N-picolyl derivatives of Kemp's triamine as potential antitumor agents: a preliminary investigation. J Med Chem 2005 0.75
78 Questions without answers. Curr Opin Oncol 2005 0.75
79 Use of green fluorescent protein to measure tumor growth in an implanted bladder tumor model. J Urol 2002 0.75